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1. Introduction 
Fabry’s disease is a hereditary defect resulting from 
the absence of galactosylgalactosylglucosylceramide: 
galactosyl hydrolase (ceramide trihexosidase); the en- 
zyme is specific for the cleavage of the terminal galac- 
tosyl unit of &galactosyl(l -+_%galactosyl( 1+4)#% 
glucosylceramide (CL-3), an intermediate in the cata- 
bolism of /3-2acetamido-2-deoxygalactosyl(1+3)-/3- 
galactosyl~1~4)-&galactosyl(1+4)~-glucosylcer- 
amide (globoside [l] . The consequence is a progressive 
accumulation of CL3 in plasma, urine and most tissues 
of patients with this X-linked disorder of glycosphin- 
golipid metabolism [2-61. Enzymatic activity has 
been found to occur in a particulate fraction from 
normal spleen, small intestine, kidney, brain and liver 
[7]. The ceramide trihexosidase is absent from small 
intestinal mucosa of males with Fabry’s disease and 
its concentration was reported to be reduced in tissue 
from one heterozygous female [l] . Plasma, lymph and 
other body fluids were not previously examined for 
enzymatic activity. 
This paper reports the occurrence of ceramide tri- 
hexosidase activity with a bimodal pH optimum in 
normal human plasma. The enzymatic activity was not 
detected in blood from hemizygous patients with 
Fabry’s disease. The level of enzymatic activity in plas- 
ma was assayed by a new method with galactose de- 
hydrogenase. 
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2. Materials and methods 
CL-3 was isolated from porcine erythrocytes by the 
method of Vance and Sweeley [8] and from Fabry 
kidney [2]. Sodium cholate, NAF and 2-(N-morphol- 
ine)ethanesulfonic acid (MES) were purchased from 
Sigma Chemical Co. (St. Louis). Citrate-phosphate 
buffer was prepared by the method of Goromi [9]. 
Galactose dehydrogenase was obtained from Boehringer- 
Mannheim Corp. (New York) and bovine serum al- 
bumin from Pentex Inc. (Kankakee). Protein was de- 
termined by the biuret method [lo] . Plasma was ob- 
tained from freshly drawn blood by centrifugation at 
7,700 g for 10 min. 
The standard reaction mixture for the assay of cer- 
amide trihexosidase consisted of plasma (0.5 ml), from 
blood collected in heparin (for analyses at pH 7 * 1) 
or EDTA (for analyses at pH 5 f 1); CL-3 (100 nmoles). 
dispersed in 0.1 ml of aqueous sodium cholate 
(0.96 mg); 0.1 ml of bovine serum albumin (5.0 mg); 
0.1 M MES buffer (pH 4.5) or citrate-phosphate buffer 
(pH 3.0) to adjust the pH of the incubation mixture 
to pH 7.2 or 5.4, respectively; and water to a total 
volume of 0.75 ml. After incubation for 4 hr at 23”, 
the reaction was terminated by addition of 2.0 ml of 
chloroform-methanol (2: 1). The suspension was mixed 
thoroughly with 0.2 ml of water and centrifuged to 
remove protein from the upper phase, which was then 
further clarified by millipore filtration. The volume of 
aqueous methanol obtained was 1.2-l .5 ml. A control 
reaction, in which CL-3 was omitted from the sodium 
cholate solution, was run with each set of samples. 
Galactose liberated from GL3 in the above reac- 
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tion was determined with an end-point assay consist- 
ing of 141 ~1 of0.1 M tris buffer (PH 8.6); 0.1 pmole 
of NAD+; 50 ~1 of upper phase from the above incu- 
bation; and 5.4 I.cg of galactose dehydrogenase (in 1 M 
(NH,.,)&) in a final volume of 0.2 ml. The increase 
in absorbance at.340 mn was measured with a Gilford 
2400 Model recording spectrophotometer thermostated 
at 30”. An absorbance change of 0.01 was equi- 
valent to 0.32 nmoles of galactose in the 50 ~1 sample. 
From the observed absorbance change, corrected for 
the control without added GL-3, galactose in the en- 
tire upper phase from the incubation with plasma was 
calculated. 
The rate of galactose formation from GL3 was 
proportional to the amount of plasma used in the 
assay. Although we have no information on the con- 
tribution of lactosylceramide: galactosyl hydrolase 
activity to the observed rate, its maximal effect if pre- 
sent in plasma would be an apparent doubling of the 
ceramide trihexosidase activity. 
3. Results and discussion 
Fig. 1 shows the curve of pH optima, which was 
similar with whole plasma and the fraction obtained 
after (NH&SO4 precipitation. Citrate-phosphate 
buffer was used for assays between pH 4.6 and 6.2, 
whereas MES buffer was used between pH 6.2 and 
8.2. The bimodal pH curve could also be demon- 
strated with citrate-phosphate buffer for assays be- 
tween pH 4.0 and 7.5. 
Ceramide trihexosidase has been found in normal The enzymatic activities of ceramide trihexosidase 
human serum and plasma. It is stable for at least 24 hr in normal and Fabry plasma are given in table 1. No 
at 0” in an unfrozen state, but activity is completely enzymatic activity could be detected in blood from 
lost on freezing. The enzyme can be recovered, with- the Fabry patients, within the limits of the method 
out loss of activity after precipitation, at 25% of sa- of assay, even when 1 ml of plasma was used in the 
turation with (NI-I&S04. incubation, and 0.1 ml of upper phase was assayed 
’ 4.6 62 7B 
PH 
Fig. 1. Effect of pH on ceramide trihexosidase activity in nor- 
mal plasma. The conditions of incubation and assay are des- 
cribed in the text. 
Table 1 
Ceramide trihexosidase activity in normal and Fabry plasma. 
Donor plasma 
Normal 
M.B. 
J.H. 
R.D. 
W.K. 
Fabry 
A.G. 
R.L. 
D.L. 
C.B. 
pH 5.4 pH 7.2 
Total units* Specific activity** Total units* Specific activity** 
16.2 0.11 30.5 0.20 
16.0 0.11 31.5 0.23 
15.7 0.13 31.4 0.27 
16.1 0.12 30.1 0.22 
< 1.5 <O.Ol < 1.5 <O.Ol 
< 1.5 <O.Ol < 1.5 <O.Ol 
< 1.5 <O.Ol < 1.5 <O.Ol 
< 1.5 <O.Ol < 1.5 <O.Ol 
* Total units: nanomoles of galactose liberated per 4 hr per 0.5 ml of plasma. 
** Specific activity: nanomoles of galactose liberated per hr per mg of protein. 
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for galactose liberated from CL-3. Thus the upper 
limit of enzymatic activity was less than 2% of that 
found in normal plasma. The assay of ceramide tri- 
hexosidase in blood can therefore be used for the 
biochemical diagnosis of hemizygotes. 
The finding of two pH optima for the ceramide 
trihexosidase activity might be explained by an ar- 
rangement of amino acid residues in the enzyme that 
allows a bimodal pH optimum. An alternative and 
more attractive explanation might be the occurrence 
of two ceramide trihexosidase isozymes, one that 
has a pH optimum of 5.4 and is similar to that pre- 
viously found in tissues (Form A), and one that has 
an optimum at pH 7.2 (Form B). The latter hypo- 
thesis is consistent with recent findings on the pre- 
sence of two forms of N-acetylhexosaminyl hydrol- 
ase in blood and various tissues, one of which is ab- 
sent in another hereditary glycosphingolipidosis, 
TaySachs disease [ 1 l] . Similarly, in Hurler’s syn- 
drome, there is a deficiency of a specific galactosyl 
hydrolase that is one of two forms with different pH 
optima [ 121. 
There are clear clinical implications of the finding 
that ceramide trihexosidase is present in normal 
human serum and absent in Fabry patients: the level 
of CL-3 in circulating plasma, which is elevated 
considerably above normal in Fabry patients [5], 
may be able to be controlled by enzyme replacement 
in the blood. 
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